CD8A and hepatocellular carcinoma: Efficiently reducing the numbers of intrahepatic CD8+ T and/or NKT cells, as well as preventing their cross-talk with hepatocytes by targeting LIGIT-LTβ R or the hedgehog pathway offers the potential to inhibit liver damage, NASH and HCC (21, 105).